Hepatorenal Syndrome

Hepatorenal syndrome is a severe renal complication of advanced cirrhosis driven by portal hypertensive circulatory dysfunction, intense renal vasoconstriction, and systemic inflammation. The most time-sensitive phenotype is HRS-AKI: AKI in a patient with cirrhosis and ascites that persists after volume expansion and exclusion of shock, nephrotoxins, and structural kidney disease. Clinically, it matters because mortality is high, diagnosis is frequently delayed, and early vasoconstrictor therapy plus albumin may reverse kidney dysfunction while liver transplantation remains the only definitive therapy (AASLD 2021, ADQI/ICA 2024.

Learning objectives

By the end of this lesson, learners should be able to:

Explain the hemodynamic and inflammatory mechanisms underlying HRS.
Briefly distinguish the major HRS phenotypes, especially HRS-AKI versus non-AKI HRS.
Apply current diagnostic criteria for HRS-AKI and distinguish it from hypovolemia, ATN, and intrinsic renal disease.
Perform a focused workup using history, physical examination, laboratory testing, urine studies, ascitic fluid analysis, and imaging.
Initiate evidence-based management, including albumin, vasoconstrictors, terlipressin safety monitoring, and early transplant planning.

HRS types

Current classification

HRS-AKI: the classic acute presentation; this is the most clinically urgent and best-studied form.
HRS-NAKI: non-AKI kidney dysfunction in cirrhosis:
- HRS-AKD: kidney dysfunction for 7-90 days
- HRS-CKD: kidney dysfunction for >90 days

Practical interpretation

Older type 1 HRS roughly maps to HRS-AKI.
Older type 2 HRS overlaps with more chronic renal dysfunction in cirrhosis, especially HRS-CKD, often in patients with refractory ascites.
In practice, most inpatient emergency decision-making centers on HRS-AKI, because evidence for albumin plus vasoconstrictors is strongest there.

(AASLD 2021, ADQI/ICA 2024, ICA AKI recommendations 2015)

Why this matters clinically

HRS-AKI demands rapid exclusion of reversible causes and prompt treatment.
HRS-AKD/HRS-CKD often require a broader chronic kidney disease evaluation, medication review, and transplant-focused longitudinal planning.
Patients can have mixed phenotypes, especially when chronic kidney dysfunction is superimposed on an acute decompensation.

(AASLD 2021, ADQI/ICA 2024)

This topic will focus on HRS-AKI

Pathophysiology

Advanced portal hypertension causes profound splanchnic arterial vasodilation.
Effective arterial blood volume falls despite total body fluid excess.
Compensatory activation of RAAS, sympathetic tone, and vasopressin causes progressive renal vasoconstriction, sodium retention, and lower GFR.
Systemic inflammation and bacterial translocation worsen microcirculatory dysfunction and may contribute to overlapping tubular injury.
Cirrhotic cardiomyopathy may blunt cardiac output augmentation and accelerate renal hypoperfusion.
Although HRS is classically described as “functional,” real-world patients often have mixed physiology, especially with infection, ACLF, or ischemic tubular injury (AASLD 2021, Bernardi et al. 2015, Csak & Chascsa 2022).

Common precipitants/differentials to look for

Spontaneous bacterial peritonitis or other infection
Gastrointestinal bleeding
Overdiuresis, vomiting, diarrhea (too much lactulose?), poor intake
Large-volume paracentesis without adequate albumin
NSAIDs, aminoglycosides, contrast, and other nephrotoxins
Hypotension, shock, or evolving ACLF

(AASLD 2021)

Diagnosis

HRS-AKI

Suspect HRS-AKI in a patient with cirrhosis, ascites, and rising creatinine/AKI after common reversible causes of AKI have been addressed.

Current diagnostic framework

Cirrhosis with ascites
AKI defined by:
- serum creatinine rise ≥0.3 mg/dL within 48 hours, or
- rise ≥50% from baseline within 7 days
No improvement after 2 days of diuretic withdrawal and plasma volume expansion with albumin 1 g/kg/day
No shock
No current/recent nephrotoxic drugs
No structural kidney injury, suggested by:
- proteinuria >500 mg/day
- microhematuria >50 RBCs/high-power field
- abnormal renal ultrasonography

(AASLD 2021, ICA AKI recommendations 2015)

Major mimics and how to think about them

Hypovolemia/prerenal AKI: fluid loss, bleeding, overdiuresis, diarrhea, improvement with resuscitation
ATN: sepsis/shock, nephrotoxins, granular casts, higher tubular injury biomarkers
Intrinsic renal disease: significant proteinuria, active urine sediment, systemic autoimmune features
Postrenal obstruction: uncommon but should be excluded with imaging

Urine sodium, FENa, and FEurea may support the differential but do not establish HRS by themselves. FENa is generally low in HRS-AKI.

(AASLD 2021, ADQI/ICA 2024)

Workup: history and physical

History

Baseline kidney function and tempo of creatinine rise
Recent diuretic escalation, poor intake, vomiting, diarrhea (lactulose escalation?), GI bleeding
Fever, abdominal pain, dysuria, cough, cellulitis, or other infection clues
Recent paracentesis and whether albumin was given
NSAIDs, ACE inhibitors/ARBs, aminoglycosides, contrast, herbal agents
Prior CKD, diabetes, hypertension, or glomerular disease

Physical examination

MAP, orthostasis, perfusion, and evidence of shock
Ascites burden, edema, and volume status
JVP, crackles, or cardiopulmonary congestion
Encephalopathy, jaundice, sarcopenia, and ACLF features
Evidence of infection source: abdominal exam, skin check, lung exam, etc
Clues to alternate causes of ascites or kidney disease

Bedside priorities

Review recent fluids, albumin exposure, urine output, and weight trajectory
In new/worsening ascites or possible infection, obtain diagnostic paracentesis
Avoid anchoring on HRS before excluding infection, bleeding, and hypovolemia (AASLD 2021).

Initial evaluation pitfalls

Assuming oliguria is required
Delaying paracentesis
Continuing nephrotoxins or aggressive diuresis during AKI evaluation
Labeling the patient as HRS before excluding ATN or obstruction
Missing heart failure physiology in a patient with pulmonary congestion or high-protein ascites

(AASLD 2021)

Workup: labs, urine, ascites, and imaging

Core tests

Urine protein quantification if intrinsic disease is a concern
Blood and urine cultures when infection is possible
Ascitic fluid PMN count and culture when infection is suspected or ascites is newly evaluated
Renal ultrasound to exclude obstruction; abdominal ultrasound/Doppler when vascular complications or alternate diagnoses are possible

What argues against pure HRS-AKI?

Active urine sediment
Significant proteinuria
Abnormal renal imaging
Clear shock physiology
A persistent alternate explanation for AKI despite resuscitation (AASLD 2021, ADQI/ICA 2024).

Management

Immediate priorities

Treat AKI as soon as recognized
Stop diuretics during the diagnostic challenge
Stop nephrotoxins
Correct hypovolemia and manage GI bleeding if present
Treat infection promptly; in SBP, albumin plus antibiotics lowers HRS/renal dysfunction risk and improves outcomes.

Consider holding nonselective beta-blockers if hypotension is contributing
Escalate to ICU/intermediate care if there is multiorgan failure, severe encephalopathy, respiratory compromise, or likely need for vasopressors/RRT
Involve hepatology, nephrology, and transplant teams early (AASLD 2021, ADQI/ICA 2024, Sort et al. 1999).

Initial management checklist

Confirm the creatinine trend against true baseline
Stop diuretics and nephrotoxins
Give albumin challenge
Search aggressively for infection, bleeding, and volume loss
Perform paracentesis when indicated
Reassess MAP, oxygenation, urine output, creatinine, and volume status daily
Trigger liver transplant evaluation early

(AASLD 2021)

Management: albumin and vasoconstrictor protocols

1) Diagnostic/initial albumin challenge

Albumin 25%: 1 g/kg/day (max 100 g/day) for up to 2 days
Use while stopping diuretics and correcting reversible precipitants
Reassess hemodynamics, urine output, creatinine, oxygenation, and signs of fluid overload after each dose (AASLD 2021, Loftus et al. 2023).

2) First-line: terlipressin + albumin

Starting dose: 0.85 mg IV every 6 hours for 3 days
Day 4 adjustment:
- if creatinine decreased ≥30% from baseline: continue 0.85 mg IV q6h
- if creatinine decreased <30%: increase to 1.7 mg IV q6h
- if creatinine is at or above baseline: discontinue
Duration: continue until 24 hours after two consecutive serum creatinine values ≤1.5 mg/dL at least 2 hours apart, or maximum 14 days
Albumin with therapy: commonly 20-40 g/day during vasoconstrictor treatment, with close reassessment because over-resuscitation increases pulmonary edema risk
Stop early if no biochemical improvement after 4 days at maximum tolerated dose (DailyMed TERLIVAZ, Loftus et al. 2023, AASLD 2021).

Terlipressin: side effects, contraindications, and monitoring

Common adverse effects: abdominal pain, nausea, diarrhea, dyspnea
Major toxicities: respiratory failure/hypoxia, pulmonary edema or fluid overload, coronary/peripheral/mesenteric ischemia
Contraindications: current hypoxia or worsening respiratory symptoms; ongoing coronary, peripheral, or mesenteric ischemia (hx of significant vascular disease)
Relative Contraindications: serum creatinine >5 mg/dL, acute on chronic liver failure rad 3 (ie, >/= organ failures), serum bilirubin >10 mg/dL
Monitoring protocol:
- baseline SpO2 before first dose
- continuous pulse oximetry during therapy
- frequent respiratory assessments and daily oxygen requirement review
- daily creatinine and urine output
- daily weight, fluid balance, edema, and pulmonary exam
- surveillance for abdominal pain out of proportion, chest pain, extremity ischemia, or rising lactate
Stop or interrupt terlipressin for hypoxia, worsening respiratory status, ischemic symptoms, or lack of biochemical response per protocol

(DailyMed TERLIVAZ, Wong et al. 2022, FDA terlipressin approval)

3) Second-line: norepinephrine + albumin

Preferred when terlipressin is unavailable or unsuitable
Start norepinephrine infusion at 5 t 8 mcg/minute
Titrate by MAP, improved urine output
Usually requires ICU-capable monitoring and central/closely supervised vasopressor administration
Coadminister albumin and reassess volume status frequently; avoid routine fluid loading when cardiopulmonary congestion is emerging (Loftus et al. 2023, AASLD 2021).

4) Third-line/fallback: midodrine + octreotide + albumin

Lowest-efficacy option; use only if terlipressin and norepinephrine cannot be given
Midodrine (starting at 7.5 to 10 mg) PO every 8 hours. Up to a maximum of 30mg TID.
Octreotide 100 μg SC every 8 hours (can go up to 200 mcg) or 50 μg/hr IV infusion. Goal to increase MAP by ~10 mmHg from baseline.
Continue until creatinine returns to baseline, up to 14 days
Albumin: commonly 20 to 40 g IV daily, then daily reassessment (Loftus et al. 2023, AASLD 2021).

Albumin can be given if the patient does not have evicence of intravascular volume overload

5) Definitive and rescue therapy

Liver transplantation is definitive treatment
RRT is mainly:
- a bridge to transplant, or
- a time-limited trial for standard indications when meaningful reversibility remains plausible (AASLD 2021, Allegretti et al. 2018).

Prognosis

HRS-AKI generally marks advanced decompensated cirrhosis and often coexists with ACLF.
Short-term mortality is high without reversal and transplant.
Even with creatinine improvement, the underlying liver disease remains life-threatening.
All patients with HRS-AKI should undergo urgent liver transplant evaluation.
RRT should be framed as:
- a bridge to liver transplantation, or
- a time-limited trial when recovery of other organ failures remains plausible
In transplant-ineligible patients, outcomes after RRT are poor and goals-of-care discussions should be early (AASLD 2021, ADQI/ICA 2024, Allegretti et al. 2018, Angeli et al. 2015).

Escalation criteria and prognostic clues

Immediate transplant escalation once HRS-AKI is suspected or confirmed
Use RRT for standard indications: refractory volume overload, severe hyperkalemia, severe acidosis, uremic complications, or worsening renal failure despite medical therapy
Poor-outcome signal: among nonlisted patients with cirrhosis started on RRT for AKI, only 15% were alive at 6 months
ACLF grade matters: it predicts short-term mortality better than AKI stage alone

(Allegretti et al. 2018, Angeli et al. 2015)

Inline dropdown unavailable.

Hepatorenal Syndrome

Learning objectives

HRS types

Current classification

Practical interpretation

Pathophysiology

Diagnosis

HRS-AKI

Workup: history and physical

History

Physical examination

Bedside priorities

Workup: labs, urine, ascites, and imaging

Core tests

What argues against pure HRS-AKI?

Management

Immediate priorities

Management: albumin and vasoconstrictor protocols

1) Diagnostic/initial albumin challenge

2) First-line: terlipressin + albumin

3) Second-line: norepinephrine + albumin

4) Third-line/fallback: midodrine + octreotide + albumin

5) Definitive and rescue therapy

Prognosis

References